Becker's Healthcare January 2, 2026
Drugmakers plan to raise U.S. prices on at least 350 branded medications beginning Jan. 1, including treatments for cancer, COVID-19 and RSV, according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.
The number of increases is up from 250 announced at the same point last year. The median list price increase is around 4%, in line with 2025. The changes do not reflect rebates or discounts negotiated with payers.
Pfizer announced the most price hikes, affecting about 80 medications, including COVID-19 vaccine Comirnaty, which will rise by 15%, and hospital-administered drugs such as morphine and hydromorphone, some of which will see fourfold increases. GSK...
Today's Sponsors
Today's Sponsor